RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027Select TIGeR-PaC Cancer Centers ...
Science Daily

Revolutionary molecular device unleashes potential for targeted drug delivery and self-healing materials

In a new breakthrough that could revolutionise medical and material engineering, scientists have developed a first-of-its-kind molecular device that controls the release of multiple small molecules ...
Nasdaq

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug ...
FiercePharma

How Merck KGaA Uses Drug Delivery Device Data to Optimize Manufacturing and Supply Chain

What work are you leading at Merck KGaA? My role is to help Merck develop drug delivery systems used to administer our injectable medicines. We have a variety of devices, including disposable and ...